Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

[1]  Robert L. Judson,et al.  Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. , 2018, Cancer cell.

[2]  O. Boyman,et al.  The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. , 2017, Cell reports.

[3]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[4]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[5]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[6]  Nam Huh,et al.  Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination , 2015, Proceedings of the National Academy of Sciences.

[7]  Nam Huh,et al.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway , 2015, Nature Genetics.

[8]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[9]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[10]  R. Dummer,et al.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors , 2015, Nature Communications.

[11]  Li Ding,et al.  Clonal Architectures and Driver Mutations in Metastatic Melanomas , 2014, PloS one.

[12]  Anne-Mette K. Hein,et al.  Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue , 2014, PloS one.

[13]  Iwei Yeh,et al.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.

[14]  Jonathan R. Pollack,et al.  The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.

[15]  Jamie K Teer,et al.  Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma , 2012, BMC Genomics.

[16]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[17]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[18]  M. Meyerson,et al.  Abstract 3178: Can DNA from archived formalin-fixed paraffin embedded (FFPE) cancer tissues be used for somatic mutation analysis in next generation sequencing , 2012 .

[19]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[20]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[21]  Ralf Herwig,et al.  Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity , 2011, BMC Medical Genomics.

[22]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[23]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[24]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[25]  Scott L Pomeroy,et al.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.

[26]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[27]  N. Dumaz,et al.  c-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes , 2010, Oncogene.

[28]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[30]  U. Rapp,et al.  Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. , 2008, The Journal of investigative dermatology.

[31]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[32]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[33]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[34]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[35]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[36]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.